Effect of fluconazole on the disposition of phenytoin. 1991

R A Blum, and J H Wilton, and D M Hilligoss, and M J Gardner, and E B Henry, and N J Harrison, and J J Schentag
Clinical Pharmacokinetics Laboratory, Millard Fillmore Hospital, Buffalo, NY 14209.

In a randomized, placebo-controlled, parallel study, phenytoin was given in the presence and absence of fluconazole. Twenty healthy male subjects received phenytoin, 200 mg orally, on study days 1 to 3 and 18 to 20 and 250 mg intravenously on study days 4 and 21. Ten subjects received fluconazole, 200 mg orally, and 10 received placebo daily on study days 8 to 21. Serial blood samples were collected during a 24-hour period after the intravenous phenytoin dose. Fluconazole trough concentrations were determined on days 14, 18, and 21. Serum phenytoin area under the concentration-time curve from 0 to 24 hours increased 75% and minimum plasma drug concentration increased 128% after administration of fluconazole, 200 mg/day, for 14 days. These values were significantly greater than the 5% increase in area under the concentration-time curve from 0 to 24 hours and 11.6% increase in minimum plasma drug concentration in the placebo group. Fluconazole trough concentrations remained unchanged during the coadministration of phenytoin. The increased phenytoin concentrations in the presence of fluconazole suggest that fluconazole inhibits phenytoin metabolism. Serum concentration monitoring with a reduction in phenytoin dosage is clinically warranted in patients receiving phenytoin and concomitant fluconazole therapy.

UI MeSH Term Description Entries
D007262 Infusions, Intravenous The long-term (minutes to hours) administration of a fluid into the vein through venipuncture, either by letting the fluid flow by gravity or by pumping it. Drip Infusions,Intravenous Drip,Intravenous Infusions,Drip Infusion,Drip, Intravenous,Infusion, Drip,Infusion, Intravenous,Infusions, Drip,Intravenous Infusion
D008297 Male Males
D010672 Phenytoin An anticonvulsant that is used to treat a wide variety of seizures. It is also an anti-arrhythmic and a muscle relaxant. The mechanism of therapeutic action is not clear, although several cellular actions have been described including effects on ion channels, active transport, and general membrane stabilization. The mechanism of its muscle relaxant effect appears to involve a reduction in the sensitivity of muscle spindles to stretch. Phenytoin has been proposed for several other therapeutic uses, but its use has been limited by its many adverse effects and interactions with other drugs. Diphenylhydantoin,Fenitoin,Phenhydan,5,5-Diphenylhydantoin,5,5-diphenylimidazolidine-2,4-dione,Antisacer,Difenin,Dihydan,Dilantin,Epamin,Epanutin,Hydantol,Phenytoin Sodium,Sodium Diphenylhydantoinate,Diphenylhydantoinate, Sodium
D011897 Random Allocation A process involving chance used in therapeutic trials or other research endeavor for allocating experimental subjects, human or animal, between treatment and control groups, or among treatment groups. It may also apply to experiments on inanimate objects. Randomization,Allocation, Random
D002851 Chromatography, High Pressure Liquid Liquid chromatographic techniques which feature high inlet pressures, high sensitivity, and high speed. Chromatography, High Performance Liquid,Chromatography, High Speed Liquid,Chromatography, Liquid, High Pressure,HPLC,High Performance Liquid Chromatography,High-Performance Liquid Chromatography,UPLC,Ultra Performance Liquid Chromatography,Chromatography, High-Performance Liquid,High-Performance Liquid Chromatographies,Liquid Chromatography, High-Performance
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D004347 Drug Interactions The action of a drug that may affect the activity, metabolism, or toxicity of another drug. Drug Interaction,Interaction, Drug,Interactions, Drug
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

R A Blum, and J H Wilton, and D M Hilligoss, and M J Gardner, and E B Henry, and N J Harrison, and J J Schentag
July 1992, British journal of clinical pharmacology,
R A Blum, and J H Wilton, and D M Hilligoss, and M J Gardner, and E B Henry, and N J Harrison, and J J Schentag
January 1994, European journal of clinical pharmacology,
R A Blum, and J H Wilton, and D M Hilligoss, and M J Gardner, and E B Henry, and N J Harrison, and J J Schentag
May 1982, Toxicology and applied pharmacology,
R A Blum, and J H Wilton, and D M Hilligoss, and M J Gardner, and E B Henry, and N J Harrison, and J J Schentag
February 1994, The Annals of pharmacotherapy,
R A Blum, and J H Wilton, and D M Hilligoss, and M J Gardner, and E B Henry, and N J Harrison, and J J Schentag
November 1989, The Medical journal of Australia,
R A Blum, and J H Wilton, and D M Hilligoss, and M J Gardner, and E B Henry, and N J Harrison, and J J Schentag
December 2003, Toxicology letters,
R A Blum, and J H Wilton, and D M Hilligoss, and M J Gardner, and E B Henry, and N J Harrison, and J J Schentag
May 1989, BMJ (Clinical research ed.),
R A Blum, and J H Wilton, and D M Hilligoss, and M J Gardner, and E B Henry, and N J Harrison, and J J Schentag
December 1990, Biopharmaceutics & drug disposition,
R A Blum, and J H Wilton, and D M Hilligoss, and M J Gardner, and E B Henry, and N J Harrison, and J J Schentag
February 2002, Journal of pediatric hematology/oncology,
R A Blum, and J H Wilton, and D M Hilligoss, and M J Gardner, and E B Henry, and N J Harrison, and J J Schentag
February 1979, The Journal of pharmacology and experimental therapeutics,
Copied contents to your clipboard!